{"protocolSection":{"identificationModule":{"nctId":"NCT01673867","orgStudyIdInfo":{"id":"CA209-057"},"secondaryIdInfos":[{"id":"2012-002472-14","type":"EUDRACT_NUMBER"}],"organization":{"fullName":"Bristol-Myers Squibb","class":"INDUSTRY"},"briefTitle":"Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Metastatic Non-squamous NSCLC","officialTitle":"An Open-Label Randomized Phase III Trial of BMS-936558 (Nivolumab) Versus Docetaxel in Previously Treated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)","acronym":"CheckMate057"},"statusModule":{"statusVerifiedDate":"2023-01","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":true,"nctId":"NCT03126643","statusForNctId":"APPROVED_FOR_MARKETING"},"startDateStruct":{"date":"2012-11-02","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2015-02-05","type":"ACTUAL"},"completionDateStruct":{"date":"2021-12-17","type":"ACTUAL"},"studyFirstSubmitDate":"2012-08-24","studyFirstSubmitQcDate":"2012-08-24","studyFirstPostDateStruct":{"date":"2012-08-28","type":"ESTIMATED"},"resultsFirstSubmitDate":"2016-01-29","resultsFirstSubmitQcDate":"2016-01-29","resultsFirstPostDateStruct":{"date":"2016-02-26","type":"ESTIMATED"},"lastUpdateSubmitDate":"2023-01-13","lastUpdatePostDateStruct":{"date":"2023-02-08","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Bristol-Myers Squibb","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The purpose of the study is to compare the overall survival of BMS-936558 (Nivolumab) as compared with Docetaxel in subjects with non-squamous cell non-small cell lung cancer (NSCLC) after failure of prior platinum-based chemotherapy","detailedDescription":"CheckMate 057: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 057"},"conditionsModule":{"conditions":["Non-Squamous Cell Non-small Cell Lung Cancer"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":582,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Arm A: Nivolumab","type":"EXPERIMENTAL","description":"Nivolumab 3 mg/kg solution intravenously (IV) every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends. Eligible patients may receive nivolumab at 480mg every 4 weeks until documented disease progression, discontinuation, withdrawal of consent or the study ends.","interventionNames":["Biological: Nivolumab"]},{"label":"Arm B: Docetaxel","type":"ACTIVE_COMPARATOR","description":"Docetaxel 75 mg/m\\^2 concentrate for solution for intravenous infusion every 3 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends. Eligible patients may receive nivolumab at 480mg every 4 weeks until documented disease progression, discontinuation, withdrawal of consent or the study ends.","interventionNames":["Drug: Docetaxel"]}],"interventions":[{"type":"BIOLOGICAL","name":"Nivolumab","armGroupLabels":["Arm A: Nivolumab"],"otherNames":["BMS-936558 (Anti-PD1)"]},{"type":"DRUG","name":"Docetaxel","armGroupLabels":["Arm B: Docetaxel"],"otherNames":["Taxotere®"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint","description":"Overall survival was defined as the time from randomization to the date of death. A participant who has not died will be censored at last known date alive. OS will be followed continuously while participants are on the study drug and every 3 months via in-person or phone contact after participants discontinue the study drug. Median and hazard ratio computed using Kaplan-Meier method.","timeFrame":"Randomization until 413 deaths, up to March 2015 (approximately 29 months)"}],"secondaryOutcomes":[{"measure":"Objective Response Rate (ORR)","description":"ORR was defined as the percentage of participants whose Best Overall Response (BOR) was a confirmed Complete Response (CR) or Partial Response (PR). BOR was defined as the best investigator-assessed response designation, recorded between the date of randomization and the date of objectively documented progression per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) or the date of subsequent anti-cancer therapy (excluding on-treatment palliative radiotherapy of non-target bone lesions or Central Nervous System (CNS) lesions), whichever occurred first. CR = Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\< 10 mm. PR = At least a 30% decrease in the sum of diameters of target lesions, taking, as reference, the baseline sum diameters. CR+PR, confidence interval based on the Clopper and Pearson method.","timeFrame":"From randomization to date of objectively documented progression (up to approximately 110 months)"},{"measure":"Time To Objective Response (TTOR)","description":"Time to Objective Response for participants demonstrating a response (either CR or PR) was defined as the time from the date of randomization to the date of the first confirmed response. CR = Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\< 10 mm.; PR = At least a 30% decrease in the sum of diameters of target lesions, taking, as reference, the baseline sum diameters.","timeFrame":"From randomization to the date of first confirmed response (up to approximately 110 months)"},{"measure":"Duration of Objective Response (DOOR)","description":"DOR was defined as the time from the date of first confirmed response to the date of the first documented tumor progression (per RECIST v1.1), as determined by the investigator, or death due to any cause, whichever occurred first. DOR was evaluated only for confirmed responders (i.e. participants with confirmed CR or PR). CR = Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\< 10 mm.; PR = At least a 30% decrease in the sum of diameters of target lesions, taking, as reference, the baseline sum diameters. Participants who neither progressed nor died were censored on the date of their last evaluable tumor assessment. Median computed using Kaplan-Meier method.","timeFrame":"From randomization to date of first documented tumor progression or death due to any cause, whichever occurred first (up to approximately 110 months)"},{"measure":"Progression-Free Survival (PFS)","description":"PFS was defined as the time from randomization to the date of the first documented tumor progression (per RECIST 1.1) or death due to any cause. Participants who died without a reported prior progression were considered to have progressed on the date of their death. Progression will be assessed every 6 weeks (from the first on-study radiographic assessment) until disease progression is noted. Progressive disease was defined as least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered progression. Median computed using the Kaplan-Meier method.","timeFrame":"From randomization to first confirmed response to the date of the first documented tumor progression or death due to any cause, whichever occurred first (up to approximately 110 months)"},{"measure":"Percentage of Participants Experiencing Disease-Related Symptom Improvement by Week 12","description":"Disease-related symptom improvement rate by Week 12 was defined as the percentage of randomized participants who had a 10 point or greater decrease from baseline in average symptom burden index score at any time between randomization and Week 12. The participant portion of the Lung Cancer Symptom Scale (LCSS) consisted of 6 symptom-specific questions that addressed cough, dyspnea, fatigue, pain, hemoptysis, and anorexia, plus 3 summary items on symptom distress, interference with activity level, and global health-related Quality of Life (QoL). The scores range from 0 to 100, with 0 representing the best possible score and 100 being the worst possible score. The average symptom burden index score at each assessment was defined as the mean of the 6 symptom-specific questions of the LCSS. 95% CIs were computed using Clopper-Pearson Method.","timeFrame":"Randomization to Week 12"},{"measure":"Overall Survival (OS) by PD-L1 Expression at Baseline","description":"Overall survival was defined as the time from randomization to the date of death. A participant who has not died will be censored at last known date alive. Overall Survival time was measured in months for all randomized participants grouped by their baseline PD-L1 expression level. PD-L1 expression in participants was defined as the percent of disease tumor cells demonstrating plasma membrane PD-L1 staining of any intensity using an immunohistochemistry (IHC) assay. Median computed using the Kaplan-Meier method.","timeFrame":"From randomization to the date of death or last known date alive (up to approximately 110 months)"},{"measure":"Objective Response Rate (ORR) by PD-L1 Expression at Baseline","description":"ORR was defined as the percentage of all randomized participants whose Best Overall Response (BOR) was a confirmed Complete Response (CR) or Partial Response (PR). CR = Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\< 10 mm.; PR = At least a 30% decrease in the sum of diameters of target lesions, taking, as reference, the baseline sum diameters. CR+PR, confidence interval based on the Clopper and Pearson method. ORR was reported for all randomized participants grouped by their baseline PD-L1 expression level. PD-L1 expression in participants was defined as the percent of disease tumor cells demonstrating plasma membrane PD-L1 staining of any intensity using an immunohistochemistry (IHC) assay.","timeFrame":"From randomization to date of objectively documented progression (up to approximately 110 months)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Men \\& women ≥18 years of age\n* Subjects with histologically or cytologically-documented non-squamous cell NSCLC who present with Stage IIIB/IV disease or recurrent or progressive disease following multimodal therapy (radiation therapy, surgical resection, or definitive chemoradiation therapy for locally advanced disease) and who will receive study therapy as second or third line of treatment for advanced disease\n* Disease recurrence or progression during/after one prior platinum doublet-based chemotherapy regimen for advanced or metastatic disease\n* Measurable disease by Computed tomography (CT)/Magnetic resonance imaging (MRI) per RECIST 1.1 criteria\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤1\n* A formalin fixed, paraffin-embedded (FFPE) tumor tissue block or unstained slides of tumor sample (archival or recent) must be available for biomarker evaluation. Specimens must be received by the central lab prior to randomization. Biopsy should be excisional, incisional or core needle. Fine needle aspiration is insufficient\n\nExclusion Criteria:\n\n* Subjects with untreated central nervous system (CNS) metastases are excluded. Subjects are eligible if CNS metastases are asymptomatic or treated and subjects are neurologically returned to baseline for at least 2 weeks prior to enrollment. In addition, subjects must be either off corticosteroids, or on a stable or decreasing dose of ≤10mg daily prednisone (or equivalent)\n* Subjects with carcinomatous meningitis\n* Subjects with active or recent history of known or suspected autoimmune disease. Subjects with Type 1 diabetes mellitus, hypothyroidism only requiring hormone replacement, or skin disorders (vitiligo, psoriasis, or alopecia) not requiring systemic treatment are permitted to enroll\n* Subjects with a condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications within 14 days of randomization\n* Prior therapy with anti-programmed death-1 (anti-PD-1), anti-programmed cell death ligand 1 (anti-PD-L1), anti-programmed cell death ligand 2 (anti-PD-L2), anti-cluster of differentiation 137 (anti-CD137), or anti-Cytotoxic T lymphocyte-associated antigen 4 (anti-CTLA-4) antibody (including Ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)\n* Prior treatment with Docetaxel\n* Treatment with any investigational agent within 14 days of first administration of study treatment\n\nOther protocol-defined inclusion/exclusion criteria apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Bristol-Myers Squibb","affiliation":"Bristol-Myers Squibb","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Mayo Clinic Arizona","city":"Scottsdale","state":"Arizona","zip":"85259","country":"United States","geoPoint":{"lat":33.50921,"lon":-111.89903}},{"facility":"Local Institution - 0009","city":"Duarte","state":"California","zip":"91010","country":"United States","geoPoint":{"lat":34.13945,"lon":-117.97729}},{"facility":"Local Institution - 0042","city":"San Diego","state":"California","zip":"92123","country":"United States","geoPoint":{"lat":32.71571,"lon":-117.16472}},{"facility":"San Francisco Oncology Associates","city":"San Francisco","state":"California","zip":"94115","country":"United States","geoPoint":{"lat":37.77493,"lon":-122.41942}},{"facility":"Yale University","city":"New Haven","state":"Connecticut","zip":"06520","country":"United States","geoPoint":{"lat":41.30815,"lon":-72.92816}},{"facility":"Local Institution - 0034","city":"Tampa","state":"Florida","zip":"33612","country":"United States","geoPoint":{"lat":27.94752,"lon":-82.45843}},{"facility":"Northwest Georgia Oncology Center, P.C.","city":"Marietta","state":"Georgia","zip":"30060","country":"United States","geoPoint":{"lat":33.9526,"lon":-84.54993}},{"facility":"Local Institution - 0030","city":"Chicago","state":"Illinois","zip":"60637","country":"United States","geoPoint":{"lat":41.85003,"lon":-87.65005}},{"facility":"The Johns Hopkins University","city":"Baltimore","state":"Maryland","zip":"21287","country":"United States","geoPoint":{"lat":39.29038,"lon":-76.61219}},{"facility":"Local Institution - 0031","city":"Boston","state":"Massachusetts","zip":"02215","country":"United States","geoPoint":{"lat":42.35843,"lon":-71.05977}},{"facility":"Local Institution - 0040","city":"Boston","state":"Massachusetts","zip":"02215","country":"United States","geoPoint":{"lat":42.35843,"lon":-71.05977}},{"facility":"Local Institution - 0138","city":"Boston","state":"Massachusetts","zip":"02215","country":"United States","geoPoint":{"lat":42.35843,"lon":-71.05977}},{"facility":"Dartmouth-Hitchcock Medical Center","city":"Lebanon","state":"New Hampshire","zip":"03756","country":"United States","geoPoint":{"lat":43.64229,"lon":-72.25176}},{"facility":"Local Institution - 0008","city":"Mineola","state":"New York","zip":"11501","country":"United States","geoPoint":{"lat":40.74927,"lon":-73.64068}},{"facility":"Local Institution - 0020","city":"New York","state":"New York","zip":"10065","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Local Institution - 0027","city":"Durham","state":"North Carolina","zip":"27710","country":"United States","geoPoint":{"lat":35.99403,"lon":-78.89862}},{"facility":"Local Institution - 0026","city":"Cincinnati","state":"Ohio","zip":"45242","country":"United States","geoPoint":{"lat":39.12711,"lon":-84.51439}},{"facility":"St. Mary Medical Center","city":"Langhorne","state":"Pennsylvania","zip":"19047","country":"United States","geoPoint":{"lat":40.17455,"lon":-74.92267}},{"facility":"Fox Chase Cancer Center","city":"Philadelphia","state":"Pennsylvania","zip":"19111","country":"United States","geoPoint":{"lat":39.95238,"lon":-75.16362}},{"facility":"Local Institution - 0035","city":"Sayre","state":"Pennsylvania","zip":"18840","country":"United States","geoPoint":{"lat":41.97896,"lon":-76.5155}},{"facility":"Local Institution - 0025","city":"Columbia","state":"South Carolina","zip":"29210","country":"United States","geoPoint":{"lat":34.00071,"lon":-81.03481}},{"facility":"Local Institution - 0024","city":"Chattanooga","state":"Tennessee","zip":"37404","country":"United States","geoPoint":{"lat":35.04563,"lon":-85.30968}},{"facility":"Local Institution - 0028","city":"Nashville","state":"Tennessee","zip":"37203","country":"United States","geoPoint":{"lat":36.16589,"lon":-86.78444}},{"facility":"Vanderbilt University Medical Center","city":"Nashville","state":"Tennessee","zip":"37232","country":"United States","geoPoint":{"lat":36.16589,"lon":-86.78444}},{"facility":"Local Institution - 0033","city":"Dallas","state":"Texas","zip":"75390","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}},{"facility":"Local Institution - 0032","city":"Houston","state":"Texas","zip":"77030","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"Local Institution - 0041","city":"Kennewick","state":"Washington","zip":"99336","country":"United States","geoPoint":{"lat":46.21125,"lon":-119.13723}},{"facility":"Swedish Cancer Institute","city":"Seattle","state":"Washington","zip":"98104","country":"United States","geoPoint":{"lat":47.60621,"lon":-122.33207}},{"facility":"Local Institution - 0007","city":"Seattle","state":"Washington","zip":"98109","country":"United States","geoPoint":{"lat":47.60621,"lon":-122.33207}},{"facility":"Local Institution - 0019","city":"Morgantown","state":"West Virginia","zip":"26506-9162","country":"United States","geoPoint":{"lat":39.62953,"lon":-79.9559}},{"facility":"Local Institution - 0010","city":"Capital Federal","state":"Buenos Aires","zip":"1426","country":"Argentina"},{"facility":"Local Institution - 0057","city":"Capital Federal","state":"Buenos Aires","zip":"1431","country":"Argentina"},{"facility":"Local Institution - 0124","city":"Ciudad de Buenos Aires","state":"Buenos Aires","zip":"C1181ACH","country":"Argentina"},{"facility":"Local Institution - 0011","city":"Buenos Aires","zip":"C1280AEB","country":"Argentina","geoPoint":{"lat":-34.61315,"lon":-58.37723}},{"facility":"Local Institution - 0125","city":"La Rioja","zip":"5300","country":"Argentina","geoPoint":{"lat":-29.41328,"lon":-66.85637}},{"facility":"Local Institution","city":"Tweed Heads","state":"New South Wales","zip":"2485","country":"Australia","geoPoint":{"lat":-28.17671,"lon":153.5452}},{"facility":"Local Institution","city":"Woolloongabba","state":"Queensland","zip":"4102","country":"Australia","geoPoint":{"lat":-27.48855,"lon":153.03655}},{"facility":"Local Institution","city":"Adelaide","state":"South Australia","zip":"5000","country":"Australia","geoPoint":{"lat":-34.92866,"lon":138.59863}},{"facility":"Local Institution","city":"Kurralta Park","state":"South Australia","zip":"5037","country":"Australia","geoPoint":{"lat":-34.95142,"lon":138.56702}},{"facility":"Local Institution","city":"Frankston","state":"Victoria","zip":"3199","country":"Australia","geoPoint":{"lat":-38.14458,"lon":145.12291}},{"facility":"Local Institution","city":"Melbourne","state":"Victoria","zip":"3065","country":"Australia","geoPoint":{"lat":-37.814,"lon":144.96332}},{"facility":"Local Institution","city":"Linz","zip":"4020","country":"Austria","geoPoint":{"lat":48.30639,"lon":14.28611}},{"facility":"Local Institution","city":"Salzburg","zip":"5020","country":"Austria","geoPoint":{"lat":47.79941,"lon":13.04399}},{"facility":"Local Institution","city":"Vienna","zip":"1130","country":"Austria","geoPoint":{"lat":48.20849,"lon":16.37208}},{"facility":"Local Institution","city":"Wels","zip":"4600","country":"Austria","geoPoint":{"lat":48.16667,"lon":14.03333}},{"facility":"Local Institution - 0056","city":"Fortaleza","state":"Ceará","zip":"60336550","country":"Brazil","geoPoint":{"lat":-3.71722,"lon":-38.54306}},{"facility":"Local Institution - 0054","city":"Salvador","state":"Estado de Bahia","zip":"40170-110","country":"Brazil","geoPoint":{"lat":-12.97563,"lon":-38.49096}},{"facility":"Local Institution - 0053","city":"Porto Alegre","state":"Rio Grande do Sul","zip":"90020-090","country":"Brazil","geoPoint":{"lat":-30.03283,"lon":-51.23019}},{"facility":"Local Institution - 0055","city":"Porto Alegre","state":"Rio Grande do Sul","zip":"90610-000","country":"Brazil","geoPoint":{"lat":-30.03283,"lon":-51.23019}},{"facility":"Local Institution - 0052","city":"Barretos","state":"São Paulo","zip":"14784-400","country":"Brazil","geoPoint":{"lat":-20.55722,"lon":-48.56778}},{"facility":"Local Institution - 0051","city":"Rio de Janeiro","zip":"20231-050","country":"Brazil","geoPoint":{"lat":-22.90642,"lon":-43.18223}},{"facility":"Local Institution - 0133","city":"Edmonton","state":"Alberta","zip":"T6G 1Z2","country":"Canada","geoPoint":{"lat":53.55014,"lon":-113.46871}},{"facility":"Local Institution","city":"London","state":"Ontario","zip":"N6A 4L6","country":"Canada","geoPoint":{"lat":42.98339,"lon":-81.23304}},{"facility":"Local Institution - 0110","city":"Rimouski","state":"Quebec","zip":"G5L 5T1","country":"Canada","geoPoint":{"lat":48.44879,"lon":-68.52396}},{"facility":"Local Institution - 0012","city":"Viña del Mar","state":"Región de Valparaíso","country":"Chile","geoPoint":{"lat":-33.02457,"lon":-71.55183}},{"facility":"Local Institution - 0058","city":"Santiago","state":"Santiago Metropolitan","zip":"7600448","country":"Chile","geoPoint":{"lat":-33.45694,"lon":-70.64827}},{"facility":"Local Institution - 0077","city":"Santiago","state":"Santiago Metropolitan","zip":"8420383","country":"Chile","geoPoint":{"lat":-33.45694,"lon":-70.64827}},{"facility":"Local Institution - 0134","city":"Santiago","state":"Santiago Metropolitan","country":"Chile","geoPoint":{"lat":-33.45694,"lon":-70.64827}},{"facility":"Local Institution - 0018","city":"Prague","zip":"180 81","country":"Czechia","geoPoint":{"lat":50.08804,"lon":14.42076}},{"facility":"Local Institution","city":"Créteil","zip":"94010","country":"France","geoPoint":{"lat":48.79266,"lon":2.46569}},{"facility":"Local Institution","city":"Dijon","zip":"21079","country":"France","geoPoint":{"lat":47.31344,"lon":5.01391}},{"facility":"Local Institution - 0119","city":"La Roche-sur-Yon","zip":"85925","country":"France","geoPoint":{"lat":46.66974,"lon":-1.42757}},{"facility":"Local Institution - 0113","city":"Lyon","zip":"69373","country":"France","geoPoint":{"lat":45.74906,"lon":4.84789}},{"facility":"Local Institution - 0112","city":"Marseille","zip":"13915","country":"France","geoPoint":{"lat":43.29695,"lon":5.38107}},{"facility":"Local Institution","city":"Poitiers","zip":"86000","country":"France","geoPoint":{"lat":46.58261,"lon":0.34348}},{"facility":"Local Institution - 0114","city":"Rennes","zip":"35033","country":"France","geoPoint":{"lat":48.11109,"lon":-1.67431}},{"facility":"Local Institution","city":"Toulouse","zip":"31300","country":"France","geoPoint":{"lat":43.60426,"lon":1.44367}},{"facility":"Local Institution","city":"Bad Berka","zip":"99437","country":"Germany","geoPoint":{"lat":50.89982,"lon":11.28245}},{"facility":"Local Institution - 0090","city":"Cologne","zip":"51109","country":"Germany","geoPoint":{"lat":50.93333,"lon":6.95}},{"facility":"Local Institution","city":"Großhansdorf","zip":"22927","country":"Germany","geoPoint":{"lat":53.66528,"lon":10.28552}},{"facility":"Local Institution","city":"Heidelberg","zip":"69126","country":"Germany","geoPoint":{"lat":49.40768,"lon":8.69079}},{"facility":"Local Institution","city":"Mainz","zip":"55131","country":"Germany","geoPoint":{"lat":49.98185,"lon":8.28008}},{"facility":"Local Institution","city":"Recklinghausen","zip":"45657","country":"Germany","geoPoint":{"lat":51.61379,"lon":7.19738}},{"facility":"Local Institution","city":"Stuttgart","zip":"70376","country":"Germany","geoPoint":{"lat":48.78232,"lon":9.17702}},{"facility":"Local Institution","city":"Ulm","zip":"89081","country":"Germany","geoPoint":{"lat":48.39841,"lon":9.99155}},{"facility":"Local Institution - 0043","city":"Hong Kong","zip":"0","country":"Hong Kong","geoPoint":{"lat":22.27832,"lon":114.17469}},{"facility":"Local Institution","city":"Hong Kong","country":"Hong Kong","geoPoint":{"lat":22.27832,"lon":114.17469}},{"facility":"Local Institution - 0074","city":"Budapest","zip":"H-1121","country":"Hungary","geoPoint":{"lat":47.49835,"lon":19.04045}},{"facility":"Local Institution - 0122","city":"Bergamo","zip":"24127","country":"Italy","geoPoint":{"lat":45.69601,"lon":9.66721}},{"facility":"Local Institution - 0086","city":"Bologna","zip":"40138","country":"Italy","geoPoint":{"lat":44.49381,"lon":11.33875}},{"facility":"Local Institution - 0087","city":"Meldola (fc)","zip":"47014","country":"Italy","geoPoint":{"lat":44.12775,"lon":12.0626}},{"facility":"Local Institution - 0085","city":"Milan","zip":"20133","country":"Italy","geoPoint":{"lat":42.78235,"lon":12.59836}},{"facility":"Local Institution - 0084","city":"Padua","zip":"35128","country":"Italy","geoPoint":{"lat":45.40797,"lon":11.88586}},{"facility":"Local Institution - 0121","city":"Parma","zip":"43100","country":"Italy","geoPoint":{"lat":44.79935,"lon":10.32618}},{"facility":"Local Institution - 0083","city":"Perugia","zip":"06132","country":"Italy","geoPoint":{"lat":43.1122,"lon":12.38878}},{"facility":"Local Institution - 0088","city":"Ravenna","zip":"48121","country":"Italy","geoPoint":{"lat":44.41344,"lon":12.20121}},{"facility":"Local Institution - 0082","city":"Siena","zip":"53100","country":"Italy","geoPoint":{"lat":43.31822,"lon":11.33064}},{"facility":"Local Institution - 0107","city":"Mexico City","state":"Mexico City","zip":"06735","country":"Mexico","geoPoint":{"lat":19.42847,"lon":-99.12766}},{"facility":"Local Institution - 0108","city":"Mexico City","state":"Mexico City","zip":"14080","country":"Mexico","geoPoint":{"lat":19.42847,"lon":-99.12766}},{"facility":"Local Institution","city":"Monterrey","state":"Nuevo León","zip":"64060","country":"Mexico","geoPoint":{"lat":25.68435,"lon":-100.31721}},{"facility":"Local Institution","city":"Hermosillo","state":"Sonora","zip":"83280","country":"Mexico","geoPoint":{"lat":29.08874,"lon":-110.96677}},{"facility":"Local Institution - 0141","city":"Oslo","zip":"0424","country":"Norway","geoPoint":{"lat":59.91273,"lon":10.74609}},{"facility":"Local Institution - 0131","city":"Miraflores","state":"Lima region","zip":"18","country":"Peru","geoPoint":{"lat":-12.11331,"lon":-77.03274}},{"facility":"Local Institution - 0050","city":"Arequipa","zip":"54","country":"Peru","geoPoint":{"lat":-16.39899,"lon":-71.53747}},{"facility":"Local Institution - 0048","city":"Lima","zip":"34","country":"Peru","geoPoint":{"lat":-12.04318,"lon":-77.02824}},{"facility":"Local Institution - 0049","city":"Lima","zip":"L-27","country":"Peru","geoPoint":{"lat":-12.04318,"lon":-77.02824}},{"facility":"Local Institution - 0073","city":"Krakow","state":"Lesser Poland Voivodeship","zip":"30-002","country":"Poland","geoPoint":{"lat":50.06143,"lon":19.93658}},{"facility":"Local Institution - 0068","city":"Gdansk","zip":"80-19","country":"Poland","geoPoint":{"lat":54.35227,"lon":18.64912}},{"facility":"Local Institution - 0072","city":"Olsztyn","zip":"10-513","country":"Poland","geoPoint":{"lat":53.78376,"lon":20.49272}},{"facility":"Local Institution - 0067","city":"Szczecin","zip":"70891","country":"Poland","geoPoint":{"lat":53.42894,"lon":14.55302}},{"facility":"Local Institution - 0070","city":"Warsaw","zip":"02-781","country":"Poland","geoPoint":{"lat":52.22977,"lon":21.01178}},{"facility":"Local Institution - 0099","city":"Bucharest","zip":"010976","country":"Romania","geoPoint":{"lat":44.43225,"lon":26.10626}},{"facility":"Local Institution - 0123","city":"Cluj-Napoca","zip":"400352","country":"Romania","geoPoint":{"lat":46.76667,"lon":23.6}},{"facility":"Local Institution - 0063","city":"Craiova","zip":"200385","country":"Romania","geoPoint":{"lat":44.31667,"lon":23.8}},{"facility":"Local Institution - 0061","city":"Iași","zip":"700106","country":"Romania","geoPoint":{"lat":47.16667,"lon":27.6}},{"facility":"Local Institution - 0062","city":"Timișoara","zip":"300167","country":"Romania","geoPoint":{"lat":45.75372,"lon":21.22571}},{"facility":"Local Institution - 0078","city":"Moscow","zip":"115 478","country":"Russia","geoPoint":{"lat":55.75204,"lon":37.61781}},{"facility":"Local Institution - 0079","city":"Moscow","zip":"115 478","country":"Russia","geoPoint":{"lat":55.75204,"lon":37.61781}},{"facility":"Local Institution - 0120","city":"Moscow","zip":"115 478","country":"Russia","geoPoint":{"lat":55.75204,"lon":37.61781}},{"facility":"Local Institution - 0080","city":"Saint Petersburg","zip":"197022","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"Local Institution","city":"Singapore","zip":"169610","country":"Singapore","geoPoint":{"lat":1.28967,"lon":103.85007}},{"facility":"Local Institution","city":"Singapore","zip":"308433","country":"Singapore","geoPoint":{"lat":1.28967,"lon":103.85007}},{"facility":"Local Institution","city":"Barcelona","zip":"08035","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Local Institution","city":"Madrid","zip":"28040","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Local Institution","city":"Madrid","zip":"28050","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Local Institution - 0001","city":"Seville","zip":"41013","country":"Spain","geoPoint":{"lat":37.38283,"lon":-5.97317}},{"facility":"Local Institution","city":"Vizcaya","zip":"48903","country":"Spain"},{"facility":"Local Institution","city":"Basel","zip":"4031","country":"Switzerland","geoPoint":{"lat":47.55839,"lon":7.57327}},{"facility":"Local Institution","city":"Chur","zip":"7000","country":"Switzerland","geoPoint":{"lat":46.84986,"lon":9.53287}}]},"referencesModule":{"references":[{"pmid":"37264091","type":"DERIVED","citation":"Barrera C, Corredor G, Viswanathan VS, Ding R, Toro P, Fu P, Buzzy C, Lu C, Velu P, Zens P, Berezowska S, Belete M, Balli D, Chang H, Baxi V, Syrigos K, Rimm DL, Velcheti V, Schalper K, Romero E, Madabhushi A. Deep computational image analysis of immune cell niches reveals treatment-specific outcome associations in lung cancer. NPJ Precis Oncol. 2023 Jun 1;7(1):52. doi: 10.1038/s41698-023-00403-x."},{"pmid":"36897427","type":"DERIVED","citation":"Hu S, Tang Z, Harrison JP, Hertel N, Penrod JR, May JR, Juarez-Garcia A, Holdgate O. Economic Evaluation of Nivolumab Versus Docetaxel for the Treatment of Advanced Squamous and Non-squamous Non-small Cell Lung Cancer After Prior Chemotherapy in China. Pharmacoecon Open. 2023 Mar;7(2):273-284. doi: 10.1007/s41669-022-00383-x. Epub 2023 Mar 10."},{"pmid":"33449799","type":"DERIVED","citation":"Borghaei H, Gettinger S, Vokes EE, Chow LQM, Burgio MA, de Castro Carpeno J, Pluzanski A, Arrieta O, Frontera OA, Chiari R, Butts C, Wojcik-Tomaszewska J, Coudert B, Garassino MC, Ready N, Felip E, Garcia MA, Waterhouse D, Domine M, Barlesi F, Antonia S, Wohlleber M, Gerber DE, Czyzewicz G, Spigel DR, Crino L, Eberhardt WEE, Li A, Marimuthu S, Brahmer J. Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer. J Clin Oncol. 2021 Mar 1;39(7):723-733. doi: 10.1200/JCO.20.01605. Epub 2021 Jan 15."},{"pmid":"30215677","type":"DERIVED","citation":"Long GV, Tykodi SS, Schneider JG, Garbe C, Gravis G, Rashford M, Agrawal S, Grigoryeva E, Bello A, Roy A, Rollin L, Zhao X. Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer. Ann Oncol. 2018 Nov 1;29(11):2208-2213. doi: 10.1093/annonc/mdy408."},{"pmid":"30103096","type":"DERIVED","citation":"Reck M, Brahmer J, Bennett B, Taylor F, Penrod JR, DeRosa M, Dastani H, Spigel DR, Gralla RJ. Evaluation of health-related quality of life and symptoms in patients with advanced non-squamous non-small cell lung cancer treated with nivolumab or docetaxel in CheckMate 057. Eur J Cancer. 2018 Oct;102:23-30. doi: 10.1016/j.ejca.2018.05.005. Epub 2018 Aug 10."},{"pmid":"29408986","type":"DERIVED","citation":"Vokes EE, Ready N, Felip E, Horn L, Burgio MA, Antonia SJ, Aren Frontera O, Gettinger S, Holgado E, Spigel D, Waterhouse D, Domine M, Garassino M, Chow LQM, Blumenschein G Jr, Barlesi F, Coudert B, Gainor J, Arrieta O, Brahmer J, Butts C, Steins M, Geese WJ, Li A, Healey D, Crino L. Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases. Ann Oncol. 2018 Apr 1;29(4):959-965. doi: 10.1093/annonc/mdy041."},{"pmid":"29023213","type":"DERIVED","citation":"Horn L, Spigel DR, Vokes EE, Holgado E, Ready N, Steins M, Poddubskaya E, Borghaei H, Felip E, Paz-Ares L, Pluzanski A, Reckamp KL, Burgio MA, Kohlhaeufl M, Waterhouse D, Barlesi F, Antonia S, Arrieta O, Fayette J, Crino L, Rizvi N, Reck M, Hellmann MD, Geese WJ, Li A, Blackwood-Chirchir A, Healey D, Brahmer J, Eberhardt WEE. Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057). J Clin Oncol. 2017 Dec 10;35(35):3924-3933. doi: 10.1200/JCO.2017.74.3062. Epub 2017 Oct 12."},{"pmid":"26412456","type":"DERIVED","citation":"Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlhaufl M, Arrieta O, Burgio MA, Fayette J, Lena H, Poddubskaya E, Gerber DE, Gettinger SN, Rudin CM, Rizvi N, Crino L, Blumenschein GR Jr, Antonia SJ, Dorange C, Harbison CT, Graf Finckenstein F, Brahmer JR. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015 Oct 22;373(17):1627-39. doi: 10.1056/NEJMoa1507643. Epub 2015 Sep 27."}],"seeAlsoLinks":[{"label":"BMS Clinical Trial Information","url":"https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html"},{"label":"BMS Clinical Trial Patient Recruiting","url":"https://www.bmsstudyconnect.com/s/US/English/USenHome"},{"label":"FDA Safety Alerts and Recalls","url":"https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm"},{"label":"Investigator Inquiry Form","url":"https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html"}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Nivolumab","description":"Nivolumab 3 mg/kg solution administered intravenously every 2 weeks. Eligible participants transitioned to nivolumab 480 mg every 4 weeks. Participants treated until disease progression, discontinuation due to toxicity, withdrawal of consent or end of study."},{"id":"FG001","title":"Docetaxel","description":"Docetaxel 75mg/m\\^2 solution administered intravenously every 3 weeks. Eligible participants transitioned to nivolumab 3 mg/kg every 2 weeks or 480 mg every 4 weeks. Participants treated until disease progression, discontinuation due to toxicity, withdrawal of consent or end of study."}],"periods":[{"title":"Randomization","milestones":[{"type":"STARTED","comment":"Started = Randomized","achievements":[{"groupId":"FG000","numSubjects":"292"},{"groupId":"FG001","numSubjects":"290"}]},{"type":"COMPLETED","comment":"Completed = Received treatment","achievements":[{"groupId":"FG000","numSubjects":"287"},{"groupId":"FG001","numSubjects":"268"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"22"}]}],"dropWithdraws":[{"type":"Adverse event unrelated to study drug","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Participant request to discontinue study treatment","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"4"}]},{"type":"Withdrawal by participant","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"12"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Participant no longer meets study criteria","reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"5"}]}]},{"title":"Treatment","milestones":[{"type":"STARTED","comment":"Started = Received treatment","achievements":[{"groupId":"FG000","numSubjects":"287"},{"groupId":"FG001","numSubjects":"268"}]},{"type":"Participants Who Transitioned to Nivolumab 3 mg/kg","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"17"}]},{"type":"Participants Who Transitioned to Nivolumab 480 mg","achievements":[{"groupId":"FG000","numSubjects":"15"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"COMPLETED","comment":"Completed = Completed treatment period","achievements":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"285"},{"groupId":"FG001","numSubjects":"268"}]}],"dropWithdraws":[{"type":"Disease Progression","reasons":[{"groupId":"FG000","numSubjects":"208"},{"groupId":"FG001","numSubjects":"178"}]},{"type":"Study Drug Toxicity","reasons":[{"groupId":"FG000","numSubjects":"23"},{"groupId":"FG001","numSubjects":"43"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"3"}]},{"type":"Adverse event unrelated to study drug","reasons":[{"groupId":"FG000","numSubjects":"23"},{"groupId":"FG001","numSubjects":"10"}]},{"type":"Participant request to discontinue study treatment","reasons":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"17"}]},{"type":"Withdrawal by participant","reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"5"}]},{"type":"Maximum clinical benefit","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"10"}]},{"type":"Participant no longer meets study criteria","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Administrative reason by sponsor","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Other reason","reasons":[{"groupId":"FG000","numSubjects":"11"},{"groupId":"FG001","numSubjects":"2"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"All randomized participants","groups":[{"id":"BG000","title":"Nivolumab","description":"Nivolumab 3 mg/kg solution administered intravenously every 2 weeks. Eligible participants transitioned to nivolumab 480 mg every 4 weeks. Participants treated until disease progression, discontinuation due to toxicity, withdrawal of consent or end of study."},{"id":"BG001","title":"Docetaxel","description":"Docetaxel 75mg/m\\^2 solution administered intravenously every 3 weeks. Eligible participants transitioned to nivolumab 3 mg/kg every 2 weeks or 480 mg every 4 weeks. Participants treated until disease progression, discontinuation due to toxicity, withdrawal of consent or end of study."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"292"},{"groupId":"BG001","value":"290"},{"groupId":"BG002","value":"582"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"60.9","spread":"9.27"},{"groupId":"BG001","value":"62.3","spread":"9.75"},{"groupId":"BG002","value":"61.6","spread":"9.53"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"141"},{"groupId":"BG001","value":"122"},{"groupId":"BG002","value":"263"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"151"},{"groupId":"BG001","value":"168"},{"groupId":"BG002","value":"319"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"American Indian or Alaska Native","categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}]}]},{"title":"Asian","categories":[{"measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"17"}]}]},{"title":"Native Hawaiian or Other Pacific Islander","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}]}]},{"title":"Black or African American","categories":[{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"16"}]}]},{"title":"White","categories":[{"measurements":[{"groupId":"BG000","value":"267"},{"groupId":"BG001","value":"266"},{"groupId":"BG002","value":"533"}]}]},{"title":"Other","categories":[{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"14"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"Hispanic or Latino","categories":[{"measurements":[{"groupId":"BG000","value":"19"},{"groupId":"BG001","value":"16"},{"groupId":"BG002","value":"35"}]}]},{"title":"Not Hispanic or Latino","categories":[{"measurements":[{"groupId":"BG000","value":"135"},{"groupId":"BG001","value":"141"},{"groupId":"BG002","value":"276"}]}]},{"title":"Not Reported","categories":[{"measurements":[{"groupId":"BG000","value":"138"},{"groupId":"BG001","value":"133"},{"groupId":"BG002","value":"271"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint","description":"Overall survival was defined as the time from randomization to the date of death. A participant who has not died will be censored at last known date alive. OS will be followed continuously while participants are on the study drug and every 3 months via in-person or phone contact after participants discontinue the study drug. Median and hazard ratio computed using Kaplan-Meier method.","populationDescription":"All randomized participants","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Randomization until 413 deaths, up to March 2015 (approximately 29 months)","groups":[{"id":"OG000","title":"Nivolumab","description":"Nivolumab 3 mg/kg solution administered intravenously every 2 weeks. Eligible participants transitioned to nivolumab 480 mg every 4 weeks. Participants treated until disease progression, discontinuation due to toxicity, withdrawal of consent or end of study."},{"id":"OG001","title":"Docetaxel","description":"Docetaxel 75mg/m\\^2 solution administered intravenously every 3 weeks. Eligible participants transitioned to nivolumab 3 mg/kg every 2 weeks or 480 mg every 4 weeks. Participants treated until disease progression, discontinuation due to toxicity, withdrawal of consent or end of study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"292"},{"groupId":"OG001","value":"290"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.19","lowerLimit":"9.66","upperLimit":"14.98"},{"groupId":"OG001","value":"9.36","lowerLimit":"8.05","upperLimit":"10.68"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0015","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.73","ciPctValue":"95.92","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.59","ciUpperLimit":"0.89","estimateComment":"HR = Nivolumab over docetaxel"}]},{"type":"SECONDARY","title":"Objective Response Rate (ORR)","description":"ORR was defined as the percentage of participants whose Best Overall Response (BOR) was a confirmed Complete Response (CR) or Partial Response (PR). BOR was defined as the best investigator-assessed response designation, recorded between the date of randomization and the date of objectively documented progression per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) or the date of subsequent anti-cancer therapy (excluding on-treatment palliative radiotherapy of non-target bone lesions or Central Nervous System (CNS) lesions), whichever occurred first. CR = Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\< 10 mm. PR = At least a 30% decrease in the sum of diameters of target lesions, taking, as reference, the baseline sum diameters. CR+PR, confidence interval based on the Clopper and Pearson method.","populationDescription":"All randomized participants","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"From randomization to date of objectively documented progression (up to approximately 110 months)","groups":[{"id":"OG000","title":"Nivolumab","description":"Nivolumab 3 mg/kg solution administered intravenously every 2 weeks. Eligible participants transitioned to nivolumab 480 mg every 4 weeks. Participants treated until disease progression, discontinuation due to toxicity, withdrawal of consent or end of study."},{"id":"OG001","title":"Docetaxel","description":"Docetaxel 75mg/m\\^2 solution administered intravenously every 3 weeks. Eligible participants transitioned to nivolumab 3 mg/kg every 2 weeks or 480 mg every 4 weeks. Participants treated until disease progression, discontinuation due to toxicity, withdrawal of consent or end of study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"292"},{"groupId":"OG001","value":"290"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.5","lowerLimit":"15.1","upperLimit":"24.5"},{"groupId":"OG001","value":"12.8","lowerLimit":"9.1","upperLimit":"17.2"}]}]}]},{"type":"SECONDARY","title":"Time To Objective Response (TTOR)","description":"Time to Objective Response for participants demonstrating a response (either CR or PR) was defined as the time from the date of randomization to the date of the first confirmed response. CR = Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\< 10 mm.; PR = At least a 30% decrease in the sum of diameters of target lesions, taking, as reference, the baseline sum diameters.","populationDescription":"All randomized participants who demonstrate partial response (PR) or complete response (CR)","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"Months","timeFrame":"From randomization to the date of first confirmed response (up to approximately 110 months)","groups":[{"id":"OG000","title":"Nivolumab","description":"Nivolumab 3 mg/kg solution administered intravenously every 2 weeks. Eligible participants transitioned to nivolumab 480 mg every 4 weeks. Participants treated until disease progression, discontinuation due to toxicity, withdrawal of consent or end of study."},{"id":"OG001","title":"Docetaxel","description":"Docetaxel 75mg/m\\^2 solution administered intravenously every 3 weeks. Eligible participants transitioned to nivolumab 3 mg/kg every 2 weeks or 480 mg every 4 weeks. Participants treated until disease progression, discontinuation due to toxicity, withdrawal of consent or end of study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"57"},{"groupId":"OG001","value":"37"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.10","lowerLimit":"1.2","upperLimit":"34.6"},{"groupId":"OG001","value":"2.73","lowerLimit":"1.4","upperLimit":"31.2"}]}]}]},{"type":"SECONDARY","title":"Duration of Objective Response (DOOR)","description":"DOR was defined as the time from the date of first confirmed response to the date of the first documented tumor progression (per RECIST v1.1), as determined by the investigator, or death due to any cause, whichever occurred first. DOR was evaluated only for confirmed responders (i.e. participants with confirmed CR or PR). CR = Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\< 10 mm.; PR = At least a 30% decrease in the sum of diameters of target lesions, taking, as reference, the baseline sum diameters. Participants who neither progressed nor died were censored on the date of their last evaluable tumor assessment. Median computed using Kaplan-Meier method.","populationDescription":"All randomized participants who demonstrate partial response (PR) or complete response (CR)","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"From randomization to date of first documented tumor progression or death due to any cause, whichever occurred first (up to approximately 110 months)","groups":[{"id":"OG000","title":"Nivolumab","description":"Nivolumab 3 mg/kg solution administered intravenously every 2 weeks. Eligible participants transitioned to nivolumab 480 mg every 4 weeks. Participants treated until disease progression, discontinuation due to toxicity, withdrawal of consent or end of study."},{"id":"OG001","title":"Docetaxel","description":"Docetaxel 75mg/m\\^2 solution administered intravenously every 3 weeks. Eligible participants transitioned to nivolumab 3 mg/kg every 2 weeks or 480 mg every 4 weeks. Participants treated until disease progression, discontinuation due to toxicity, withdrawal of consent or end of study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"57"},{"groupId":"OG001","value":"37"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.15","lowerLimit":"10.78","upperLimit":"30.75"},{"groupId":"OG001","value":"5.55","lowerLimit":"4.40","upperLimit":"7.03"}]}]}]},{"type":"SECONDARY","title":"Progression-Free Survival (PFS)","description":"PFS was defined as the time from randomization to the date of the first documented tumor progression (per RECIST 1.1) or death due to any cause. Participants who died without a reported prior progression were considered to have progressed on the date of their death. Progression will be assessed every 6 weeks (from the first on-study radiographic assessment) until disease progression is noted. Progressive disease was defined as least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered progression. Median computed using the Kaplan-Meier method.","populationDescription":"All randomized participants","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"From randomization to first confirmed response to the date of the first documented tumor progression or death due to any cause, whichever occurred first (up to approximately 110 months)","groups":[{"id":"OG000","title":"Nivolumab","description":"Nivolumab 3 mg/kg solution administered intravenously every 2 weeks. Eligible participants transitioned to nivolumab 480 mg every 4 weeks. Participants treated until disease progression, discontinuation due to toxicity, withdrawal of consent or end of study."},{"id":"OG001","title":"Docetaxel","description":"Docetaxel 75mg/m\\^2 solution administered intravenously every 3 weeks. Eligible participants transitioned to nivolumab 3 mg/kg every 2 weeks or 480 mg every 4 weeks. Participants treated until disease progression, discontinuation due to toxicity, withdrawal of consent or end of study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"292"},{"groupId":"OG001","value":"290"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.33","lowerLimit":"2.17","upperLimit":"3.32"},{"groupId":"OG001","value":"4.44","lowerLimit":"3.45","upperLimit":"4.86"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Experiencing Disease-Related Symptom Improvement by Week 12","description":"Disease-related symptom improvement rate by Week 12 was defined as the percentage of randomized participants who had a 10 point or greater decrease from baseline in average symptom burden index score at any time between randomization and Week 12. The participant portion of the Lung Cancer Symptom Scale (LCSS) consisted of 6 symptom-specific questions that addressed cough, dyspnea, fatigue, pain, hemoptysis, and anorexia, plus 3 summary items on symptom distress, interference with activity level, and global health-related Quality of Life (QoL). The scores range from 0 to 100, with 0 representing the best possible score and 100 being the worst possible score. The average symptom burden index score at each assessment was defined as the mean of the 6 symptom-specific questions of the LCSS. 95% CIs were computed using Clopper-Pearson Method.","populationDescription":"All randomized participants","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Randomization to Week 12","groups":[{"id":"OG000","title":"Nivolumab","description":"Nivolumab 3 mg/kg solution administered intravenously every 2 weeks. Eligible participants transitioned to nivolumab 480 mg every 4 weeks. Participants treated until disease progression, discontinuation due to toxicity, withdrawal of consent or end of study."},{"id":"OG001","title":"Docetaxel","description":"Docetaxel 75mg/m\\^2 solution administered intravenously every 3 weeks. Eligible participants transitioned to nivolumab 3 mg/kg every 2 weeks or 480 mg every 4 weeks. Participants treated until disease progression, discontinuation due to toxicity, withdrawal of consent or end of study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"292"},{"groupId":"OG001","value":"290"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.8","lowerLimit":"13.6","upperLimit":"22.7"},{"groupId":"OG001","value":"19.7","lowerLimit":"15.2","upperLimit":"24.7"}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS) by PD-L1 Expression at Baseline","description":"Overall survival was defined as the time from randomization to the date of death. A participant who has not died will be censored at last known date alive. Overall Survival time was measured in months for all randomized participants grouped by their baseline PD-L1 expression level. PD-L1 expression in participants was defined as the percent of disease tumor cells demonstrating plasma membrane PD-L1 staining of any intensity using an immunohistochemistry (IHC) assay. Median computed using the Kaplan-Meier method.","populationDescription":"All randomized participants who had a tumor biopsy assessed for PD-L1 expression","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"From randomization to the date of death or last known date alive (up to approximately 110 months)","groups":[{"id":"OG000","title":"Nivolumab","description":"Nivolumab 3 mg/kg solution administered intravenously every 2 weeks. Eligible participants transitioned to nivolumab 480 mg every 4 weeks. Participants treated until disease progression, discontinuation due to toxicity, withdrawal of consent or end of study."},{"id":"OG001","title":"Docetaxel","description":"Docetaxel 75mg/m\\^2 solution administered intravenously every 3 weeks. Eligible participants transitioned to nivolumab 3 mg/kg every 2 weeks or 480 mg every 4 weeks. Participants treated until disease progression, discontinuation due to toxicity, withdrawal of consent or end of study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"231"},{"groupId":"OG001","value":"224"}]}],"classes":[{"title":"Participants with baseline PD-L1 expression ≥ 5%","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"94"},{"groupId":"OG001","value":"86"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"19.91","lowerLimit":"15.08","upperLimit":"26.12"},{"groupId":"OG001","value":"8.11","lowerLimit":"6.47","upperLimit":"10.05"}]}]},{"title":"Participants with baseline PD-L1 expression < 5%","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"137"},{"groupId":"OG001","value":"138"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9.86","lowerLimit":"6.93","upperLimit":"12.81"},{"groupId":"OG001","value":"10.28","lowerLimit":"8.54","upperLimit":"11.96"}]}]}]},{"type":"SECONDARY","title":"Objective Response Rate (ORR) by PD-L1 Expression at Baseline","description":"ORR was defined as the percentage of all randomized participants whose Best Overall Response (BOR) was a confirmed Complete Response (CR) or Partial Response (PR). CR = Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\< 10 mm.; PR = At least a 30% decrease in the sum of diameters of target lesions, taking, as reference, the baseline sum diameters. CR+PR, confidence interval based on the Clopper and Pearson method. ORR was reported for all randomized participants grouped by their baseline PD-L1 expression level. PD-L1 expression in participants was defined as the percent of disease tumor cells demonstrating plasma membrane PD-L1 staining of any intensity using an immunohistochemistry (IHC) assay.","populationDescription":"All randomized participants who had a tumor biopsy assessed for PD-L1 expression","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"From randomization to date of objectively documented progression (up to approximately 110 months)","groups":[{"id":"OG000","title":"Nivolumab","description":"Nivolumab 3 mg/kg solution administered intravenously every 2 weeks. Eligible participants transitioned to nivolumab 480 mg every 4 weeks. Participants treated until disease progression, discontinuation due to toxicity, withdrawal of consent or end of study."},{"id":"OG001","title":"Docetaxel","description":"Docetaxel 75mg/m\\^2 solution administered intravenously every 3 weeks. Eligible participants transitioned to nivolumab 3 mg/kg every 2 weeks or 480 mg every 4 weeks. Participants treated until disease progression, discontinuation due to toxicity, withdrawal of consent or end of study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"231"},{"groupId":"OG001","value":"224"}]}],"classes":[{"title":"Participants with baseline PD-L1 expression ≥ 5%","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"94"},{"groupId":"OG001","value":"86"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"36.2","lowerLimit":"26.5","upperLimit":"46.7"},{"groupId":"OG001","value":"12.8","lowerLimit":"6.6","upperLimit":"21.7"}]}]},{"title":"Participants with baseline PD-L1 expression < 5%","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"137"},{"groupId":"OG001","value":"138"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10.9","lowerLimit":"6.3","upperLimit":"17.4"},{"groupId":"OG001","value":"14.5","lowerLimit":"9.1","upperLimit":"21.5"}]}]}]},{"type":"POST_HOC","title":"Overall Survival (OS) - Extended Collection","description":"Overall survival was defined as the time from randomization to the date of death. A participant who has not died will be censored at last known date alive. OS will be followed continuously while participants are on the study drug and every 3 months via in-person or phone contact after participants discontinue the study drug. Median computed using Kaplan-Meier method. Note: This outcome measure represents an updated version of the primary endpoint to include additional data collection that has occurred after the primary completion date. (Assessments were made until December 17, 2021).","populationDescription":"All randomized participants","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"From randomization to the date of death or last known date alive (up to approximately 110 months)","groups":[{"id":"OG000","title":"Nivolumab","description":"Nivolumab 3 mg/kg solution administered intravenously every 2 weeks. Eligible participants transitioned to nivolumab 480 mg every 4 weeks. Participants treated until disease progression, discontinuation due to toxicity, withdrawal of consent or end of study."},{"id":"OG001","title":"Docetaxel","description":"Docetaxel 75mg/m\\^2 solution administered intravenously every 3 weeks. Eligible participants transitioned to nivolumab 3 mg/kg every 2 weeks or 480 mg every 4 weeks. Participants treated until disease progression, discontinuation due to toxicity, withdrawal of consent or end of study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"292"},{"groupId":"OG001","value":"290"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.21","lowerLimit":"9.66","upperLimit":"15.08"},{"groupId":"OG001","value":"9.49","lowerLimit":"8.11","upperLimit":"10.74"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Participants were assessed for all-cause mortality from randomization until study completion (up to approximately 110 months). SAEs and Other AEs were assessed from first dose to 100 days after last dose of study therapy (up to approximately 108 months).","description":"All-Cause Mortality = all randomized participants. Serious Adverse Events and Other Adverse Events = all treated participants.\n\nARM 1: AEs that occurred on 3 mg/kg Nivolumab, ARM 2: AEs that occurred on 480 mg Nivolumab, ARM 3: AEs that occurred on Docetaxel treatment only, ARM 4: Extension phase of Docetaxel arm: AEs that occurred on 3 mg/kg Nivolumab, ARM 5: Extension phase of Docetaxel arm: AEs that occurred on or 480 mg Nivolumab.","eventGroups":[{"id":"EG000","title":"Nivolumab 3 mg/kg","description":"Nivolumab 3 mg/kg solution administered intravenously every 2 weeks. Participants treated until disease progression, discontinuation due to toxicity, withdrawal of consent or end of study.","deathsNumAffected":258,"deathsNumAtRisk":292,"seriousNumAffected":172,"seriousNumAtRisk":287,"otherNumAffected":267,"otherNumAtRisk":287},{"id":"EG001","title":"Nivolumab 480 mg","description":"Nivolumab 480 mg solution administered intravenously every 4 weeks. Participants treated until disease progression, discontinuation due to toxicity, withdrawal of consent or end of study.","deathsNumAffected":2,"deathsNumAtRisk":15,"seriousNumAffected":5,"seriousNumAtRisk":15,"otherNumAffected":12,"otherNumAtRisk":15},{"id":"EG002","title":"Docetaxel","description":"Docetaxel 75mg/m\\^2 solution administered intravenously every 3 weeks. Participants treated until disease progression, discontinuation due to toxicity, withdrawal of consent or end of study.","deathsNumAffected":266,"deathsNumAtRisk":290,"seriousNumAffected":161,"seriousNumAtRisk":268,"otherNumAffected":258,"otherNumAtRisk":268},{"id":"EG003","title":"Extension Phase of Docetaxel Arm: Nivolumab 3 mg/kg","description":"Eligible participants from the Docetaxel arm who transitioned to nivolumab 3 mg/kg every 2 weeks via extension phase. Participants treated until disease progression, discontinuation due to toxicity, withdrawal of consent or end of study.","deathsNumAffected":14,"deathsNumAtRisk":17,"seriousNumAffected":9,"seriousNumAtRisk":17,"otherNumAffected":12,"otherNumAtRisk":17},{"id":"EG004","title":"Extension Phase of Docetaxel Arm: Nivolumab 480 mg","description":"Eligible participants from the Docetaxel arm who transitioned to nivolumab 480 mg every 4 weeks via extension phase. Participants treated until disease progression, discontinuation due to toxicity, withdrawal of consent or end of study.","deathsNumAffected":0,"deathsNumAtRisk":1,"seriousNumAffected":1,"seriousNumAtRisk":1,"otherNumAffected":1,"otherNumAtRisk":1}],"seriousEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":4,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Febrile neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":24,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Haematotoxicity","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":1,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":1,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":8,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Thrombotic thrombocytopenic purpura","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":1,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":2,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Atrial flutter","organSystem":"Cardiac disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":1,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Cardiac arrest","organSystem":"Cardiac disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Cardiac failure","organSystem":"Cardiac disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":1,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Cardiac tamponade","organSystem":"Cardiac disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":1,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Cardio-respiratory arrest","organSystem":"Cardiac disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Cardiopulmonary failure","organSystem":"Cardiac disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Cardiovascular disorder","organSystem":"Cardiac disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":1,"numAtRisk":1}]},{"term":"Pericardial effusion","organSystem":"Cardiac disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":3,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Pericarditis","organSystem":"Cardiac disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":1,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Sinus node dysfunction","organSystem":"Cardiac disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Vertigo","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":1,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Adrenal insufficiency","organSystem":"Endocrine disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Retinal tear","organSystem":"Eye disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":3,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Ascites","organSystem":"Gastrointestinal disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":1,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Colitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":1,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Dysphagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Erosive oesophagitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":1,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Haematemesis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":2,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Inguinal hernia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Intestinal perforation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Large intestine perforation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":1,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":4,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Salivary hypersecretion","organSystem":"Gastrointestinal disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Small intestinal obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":1,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Upper gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":1,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":1,"numAtRisk":268},{"groupId":"EG003","numAffected":1,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":3,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Complication associated with device","organSystem":"General disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Disease progression","organSystem":"General disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":3,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":2,"numAtRisk":268},{"groupId":"EG003","numAffected":1,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Gait disturbance","organSystem":"General disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"General physical health deterioration","organSystem":"General disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":4,"numAtRisk":268},{"groupId":"EG003","numAffected":1,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Inflammation","organSystem":"General disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":1,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Mucosal inflammation","organSystem":"General disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":1,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Multiple organ dysfunction syndrome","organSystem":"General disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":1,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":4,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":4,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Sudden death","organSystem":"General disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":3,"numAtRisk":268},{"groupId":"EG003","numAffected":1,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Cholecystitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Cholelithiasis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Hepatotoxicity","organSystem":"Hepatobiliary disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":287},{"groupId":"EG001","numAffected":1,"numAtRisk":15},{"groupId":"EG002","numAffected":5,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"COVID-19","organSystem":"Infections and infestations","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":287},{"groupId":"EG001","numAffected":1,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":1,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Clostridium difficile colitis","organSystem":"Infections and infestations","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":1,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Device related infection","organSystem":"Infections and infestations","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":287},{"groupId":"EG001","numAffected":1,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Encephalitis","organSystem":"Infections and infestations","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Febrile infection","organSystem":"Infections and infestations","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":287},{"groupId":"EG001","numAffected":1,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Fungal oesophagitis","organSystem":"Infections and infestations","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":1,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Gastroenteritis norovirus","organSystem":"Infections and infestations","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Infected skin ulcer","organSystem":"Infections and infestations","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Infection","organSystem":"Infections and infestations","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":2,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Lower respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":1,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Lung abscess","organSystem":"Infections and infestations","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Nail infection","organSystem":"Infections and infestations","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":1,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Osteomyelitis","organSystem":"Infections and infestations","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Pneumocystis jirovecii pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":22,"numAtRisk":287},{"groupId":"EG001","numAffected":1,"numAtRisk":15},{"groupId":"EG002","numAffected":18,"numAtRisk":268},{"groupId":"EG003","numAffected":1,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Pneumonia bacterial","organSystem":"Infections and infestations","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Pneumonia mycoplasmal","organSystem":"Infections and infestations","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":1,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Pneumonia necrotising","organSystem":"Infections and infestations","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":1,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Post procedural pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":1,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Postoperative wound infection","organSystem":"Infections and infestations","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Pulmonary sepsis","organSystem":"Infections and infestations","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":3,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":1,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Septic shock","organSystem":"Infections and infestations","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":1,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Spontaneous bacterial peritonitis","organSystem":"Infections and infestations","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Staphylococcal sepsis","organSystem":"Infections and infestations","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":1,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":1,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Vascular device infection","organSystem":"Infections and infestations","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":1,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Craniocerebral injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Femur fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":287},{"groupId":"EG001","numAffected":1,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Infusion related reaction","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Pelvic fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":287},{"groupId":"EG001","numAffected":1,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Radius fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Thoracic vertebral fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":2,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Wound dehiscence","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":1,"numAtRisk":1}]},{"term":"Wrist fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"General physical condition abnormal","organSystem":"Investigations","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":2,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":1,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Transaminases increased","organSystem":"Investigations","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"White blood cell count decreased","organSystem":"Investigations","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":6,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":2,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Hypomagnesaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":1,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":1,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":4,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Bone pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Fistula","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Joint range of motion decreased","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":1,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Muscular weakness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":2,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Musculoskeletal chest pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Osteonecrosis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Osteonecrosis of jaw","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Osteoporosis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Osteoporotic fracture","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":2,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Pathological fracture","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":1,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Polymyalgia rheumatica","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Spinal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":1,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Basal cell carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Bladder transitional cell carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Bladder transitional cell carcinoma recurrent","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Breast cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Cancer pain","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Invasive ductal breast carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Lung cancer metastatic","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":1,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Lymphangiosis carcinomatosa","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Malignant neoplasm progression","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":58,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":40,"numAtRisk":268},{"groupId":"EG003","numAffected":2,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Malignant pleural effusion","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":1,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Metastases to bone","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":2,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Metastases to central nervous system","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":3,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Metastases to meninges","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Metastases to spine","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":1,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Myelodysplastic syndrome","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Neoplasm malignant","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":1,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Neoplasm progression","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":1,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Non-small cell lung cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":10,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Non-small cell lung cancer metastatic","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Oncologic complication","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":1,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Ovarian neoplasm","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Pericardial effusion malignant","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":1,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Carotid artery stenosis","organSystem":"Nervous system disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Central nervous system necrosis","organSystem":"Nervous system disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":1,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Cerebrovascular accident","organSystem":"Nervous system disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Depressed level of consciousness","organSystem":"Nervous system disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Epilepsy","organSystem":"Nervous system disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":1,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Hemiparesis","organSystem":"Nervous system disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Hemiplegia","organSystem":"Nervous system disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Hydrocephalus","organSystem":"Nervous system disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"IVth nerve paresis","organSystem":"Nervous system disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":1,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Nervous system disorder","organSystem":"Nervous system disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":2,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Neuralgia","organSystem":"Nervous system disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Partial seizures","organSystem":"Nervous system disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":1,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Sciatica","organSystem":"Nervous system disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":1,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Seizure","organSystem":"Nervous system disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":1,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Somnolence","organSystem":"Nervous system disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":2,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Spinal cord compression","organSystem":"Nervous system disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":1,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Confusional state","organSystem":"Psychiatric disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Disorientation","organSystem":"Psychiatric disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":1,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Mental status changes","organSystem":"Psychiatric disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":3,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Panic attack","organSystem":"Psychiatric disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Psychotic disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":1,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Acute kidney injury","organSystem":"Renal and urinary disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Haematuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Renal failure","organSystem":"Renal and urinary disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Tubulointerstitial nephritis","organSystem":"Renal and urinary disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Urinary retention","organSystem":"Renal and urinary disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":1,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Acute respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":4,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Chronic obstructive pulmonary disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":287},{"groupId":"EG001","numAffected":1,"numAtRisk":15},{"groupId":"EG002","numAffected":1,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":287},{"groupId":"EG001","numAffected":1,"numAtRisk":15},{"groupId":"EG002","numAffected":8,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Dyspnoea at rest","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Dyspnoea exertional","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":1,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":3,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Hiccups","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":1,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Hydrothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":1,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Hypoxia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":2,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Interstitial lung disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Lung infiltration","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":4,"numAtRisk":268},{"groupId":"EG003","numAffected":1,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Pneumonitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Pneumothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":287},{"groupId":"EG001","numAffected":2,"numAtRisk":15},{"groupId":"EG002","numAffected":1,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":13,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":5,"numAtRisk":268},{"groupId":"EG003","numAffected":1,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Pulmonary haemorrhage","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Respiratory disorder","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":1,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":4,"numAtRisk":268},{"groupId":"EG003","numAffected":1,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Deep vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":2,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Embolism","organSystem":"Vascular disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":2,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Jugular vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":1,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Peripheral artery occlusion","organSystem":"Vascular disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Peripheral artery stenosis","organSystem":"Vascular disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Venous thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":1,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":37,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":68,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":29,"numAtRisk":268},{"groupId":"EG003","numAffected":1,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":82,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Hypothyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":21,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":2,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Lacrimation increased","organSystem":"Eye disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":22,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":19,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":16,"numAtRisk":268},{"groupId":"EG003","numAffected":1,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":14,"numAtRisk":268},{"groupId":"EG003","numAffected":1,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":69,"numAtRisk":287},{"groupId":"EG001","numAffected":2,"numAtRisk":15},{"groupId":"EG002","numAffected":50,"numAtRisk":268},{"groupId":"EG003","numAffected":2,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":57,"numAtRisk":287},{"groupId":"EG001","numAffected":2,"numAtRisk":15},{"groupId":"EG002","numAffected":74,"numAtRisk":268},{"groupId":"EG003","numAffected":2,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":72,"numAtRisk":287},{"groupId":"EG001","numAffected":2,"numAtRisk":15},{"groupId":"EG002","numAffected":85,"numAtRisk":268},{"groupId":"EG003","numAffected":4,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":24,"numAtRisk":268},{"groupId":"EG003","numAffected":1,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":44,"numAtRisk":287},{"groupId":"EG001","numAffected":3,"numAtRisk":15},{"groupId":"EG002","numAffected":30,"numAtRisk":268},{"groupId":"EG003","numAffected":1,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":60,"numAtRisk":287},{"groupId":"EG001","numAffected":1,"numAtRisk":15},{"groupId":"EG002","numAffected":63,"numAtRisk":268},{"groupId":"EG003","numAffected":1,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":96,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":104,"numAtRisk":268},{"groupId":"EG003","numAffected":7,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Mucosal inflammation","organSystem":"General disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":19,"numAtRisk":268},{"groupId":"EG003","numAffected":1,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":17,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":18,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":36,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":46,"numAtRisk":268},{"groupId":"EG003","numAffected":1,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":21,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":19,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":37,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":44,"numAtRisk":268},{"groupId":"EG003","numAffected":1,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":14,"numAtRisk":287},{"groupId":"EG001","numAffected":2,"numAtRisk":15},{"groupId":"EG002","numAffected":11,"numAtRisk":268},{"groupId":"EG003","numAffected":1,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":287},{"groupId":"EG001","numAffected":2,"numAtRisk":15},{"groupId":"EG002","numAffected":16,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":19,"numAtRisk":287},{"groupId":"EG001","numAffected":1,"numAtRisk":15},{"groupId":"EG002","numAffected":13,"numAtRisk":268},{"groupId":"EG003","numAffected":2,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":20,"numAtRisk":287},{"groupId":"EG001","numAffected":1,"numAtRisk":15},{"groupId":"EG002","numAffected":6,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":14,"numAtRisk":287},{"groupId":"EG001","numAffected":1,"numAtRisk":15},{"groupId":"EG002","numAffected":3,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":18,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":28,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":21,"numAtRisk":268},{"groupId":"EG003","numAffected":1,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"White blood cell count decreased","organSystem":"Investigations","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":22,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":91,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":64,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":1,"numAtRisk":1}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":15,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":15,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":72,"numAtRisk":287},{"groupId":"EG001","numAffected":3,"numAtRisk":15},{"groupId":"EG002","numAffected":41,"numAtRisk":268},{"groupId":"EG003","numAffected":1,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":45,"numAtRisk":287},{"groupId":"EG001","numAffected":2,"numAtRisk":15},{"groupId":"EG002","numAffected":18,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Musculoskeletal chest pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":18,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":14,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Musculoskeletal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":15,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":8,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":20,"numAtRisk":287},{"groupId":"EG001","numAffected":2,"numAtRisk":15},{"groupId":"EG002","numAffected":35,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":29,"numAtRisk":287},{"groupId":"EG001","numAffected":1,"numAtRisk":15},{"groupId":"EG002","numAffected":30,"numAtRisk":268},{"groupId":"EG003","numAffected":1,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":30,"numAtRisk":287},{"groupId":"EG001","numAffected":1,"numAtRisk":15},{"groupId":"EG002","numAffected":25,"numAtRisk":268},{"groupId":"EG003","numAffected":1,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Dysgeusia","organSystem":"Nervous system disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":20,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":1,"numAtRisk":1}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":33,"numAtRisk":287},{"groupId":"EG001","numAffected":1,"numAtRisk":15},{"groupId":"EG002","numAffected":35,"numAtRisk":268},{"groupId":"EG003","numAffected":1,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Neuropathy peripheral","organSystem":"Nervous system disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":28,"numAtRisk":268},{"groupId":"EG003","numAffected":2,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Paraesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":14,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":25,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Peripheral sensory neuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":14,"numAtRisk":268},{"groupId":"EG003","numAffected":1,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":18,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":8,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":25,"numAtRisk":287},{"groupId":"EG001","numAffected":2,"numAtRisk":15},{"groupId":"EG002","numAffected":23,"numAtRisk":268},{"groupId":"EG003","numAffected":1,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":83,"numAtRisk":287},{"groupId":"EG001","numAffected":5,"numAtRisk":15},{"groupId":"EG002","numAffected":67,"numAtRisk":268},{"groupId":"EG003","numAffected":6,"numAtRisk":17},{"groupId":"EG004","numAffected":1,"numAtRisk":1}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":68,"numAtRisk":287},{"groupId":"EG001","numAffected":1,"numAtRisk":15},{"groupId":"EG002","numAffected":64,"numAtRisk":268},{"groupId":"EG003","numAffected":6,"numAtRisk":17},{"groupId":"EG004","numAffected":1,"numAtRisk":1}]},{"term":"Dyspnoea exertional","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":19,"numAtRisk":268},{"groupId":"EG003","numAffected":1,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":16,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":15,"numAtRisk":268},{"groupId":"EG003","numAffected":1,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Nasal congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":14,"numAtRisk":287},{"groupId":"EG001","numAffected":1,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Oropharyngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":287},{"groupId":"EG001","numAffected":1,"numAtRisk":15},{"groupId":"EG002","numAffected":16,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Productive cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":16,"numAtRisk":287},{"groupId":"EG001","numAffected":1,"numAtRisk":15},{"groupId":"EG002","numAffected":10,"numAtRisk":268},{"groupId":"EG003","numAffected":1,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":70,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Dry skin","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":24,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":9,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Erythema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":287},{"groupId":"EG001","numAffected":1,"numAtRisk":15},{"groupId":"EG002","numAffected":18,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":37,"numAtRisk":287},{"groupId":"EG001","numAffected":1,"numAtRisk":15},{"groupId":"EG002","numAffected":7,"numAtRisk":268},{"groupId":"EG003","numAffected":2,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":41,"numAtRisk":287},{"groupId":"EG001","numAffected":3,"numAtRisk":15},{"groupId":"EG002","numAffected":18,"numAtRisk":268},{"groupId":"EG003","numAffected":2,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":14,"numAtRisk":287},{"groupId":"EG001","numAffected":2,"numAtRisk":15},{"groupId":"EG002","numAffected":4,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Lymphadenopathy","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":1,"numAtRisk":268},{"groupId":"EG003","numAffected":1,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":3,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":1,"numAtRisk":1}]},{"term":"Myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":1,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Pericardial effusion","organSystem":"Cardiac disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":1,"numAtRisk":268},{"groupId":"EG003","numAffected":1,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":8,"numAtRisk":268},{"groupId":"EG003","numAffected":1,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Ear pain","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":287},{"groupId":"EG001","numAffected":1,"numAtRisk":15},{"groupId":"EG002","numAffected":1,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Excessive cerumen production","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":287},{"groupId":"EG001","numAffected":1,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Hypoacusis","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":3,"numAtRisk":268},{"groupId":"EG003","numAffected":1,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Tympanic membrane perforation","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":287},{"groupId":"EG001","numAffected":1,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Hyperthyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":1,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":12,"numAtRisk":268},{"groupId":"EG003","numAffected":1,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Dysphagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":287},{"groupId":"EG001","numAffected":1,"numAtRisk":15},{"groupId":"EG002","numAffected":8,"numAtRisk":268},{"groupId":"EG003","numAffected":1,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Chest discomfort","organSystem":"General disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":287},{"groupId":"EG001","numAffected":1,"numAtRisk":15},{"groupId":"EG002","numAffected":1,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":287},{"groupId":"EG001","numAffected":1,"numAtRisk":15},{"groupId":"EG002","numAffected":6,"numAtRisk":268},{"groupId":"EG003","numAffected":1,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Influenza like illness","organSystem":"General disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":3,"numAtRisk":268},{"groupId":"EG003","numAffected":1,"numAtRisk":17},{"groupId":"EG004","numAffected":1,"numAtRisk":1}]},{"term":"Nodule","organSystem":"General disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":1,"numAtRisk":15},{"groupId":"EG002","numAffected":1,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Swelling","organSystem":"General disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":1,"numAtRisk":15},{"groupId":"EG002","numAffected":1,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":287},{"groupId":"EG001","numAffected":2,"numAtRisk":15},{"groupId":"EG002","numAffected":7,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Campylobacter infection","organSystem":"Infections and infestations","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":287},{"groupId":"EG001","numAffected":1,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Candida infection","organSystem":"Infections and infestations","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":5,"numAtRisk":268},{"groupId":"EG003","numAffected":1,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Conjunctivitis","organSystem":"Infections and infestations","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":287},{"groupId":"EG001","numAffected":1,"numAtRisk":15},{"groupId":"EG002","numAffected":4,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Lower respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":1,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Oral candidiasis","organSystem":"Infections and infestations","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":3,"numAtRisk":268},{"groupId":"EG003","numAffected":1,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":3,"numAtRisk":268},{"groupId":"EG003","numAffected":1,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Sinusitis","organSystem":"Infections and infestations","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":13,"numAtRisk":287},{"groupId":"EG001","numAffected":1,"numAtRisk":15},{"groupId":"EG002","numAffected":3,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":13,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":9,"numAtRisk":268},{"groupId":"EG003","numAffected":1,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":287},{"groupId":"EG001","numAffected":1,"numAtRisk":15},{"groupId":"EG002","numAffected":1,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Meniscus injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":287},{"groupId":"EG001","numAffected":1,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Amylase increased","organSystem":"Investigations","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":287},{"groupId":"EG001","numAffected":1,"numAtRisk":15},{"groupId":"EG002","numAffected":1,"numAtRisk":268},{"groupId":"EG003","numAffected":1,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Blood alkaline phosphatase increased","organSystem":"Investigations","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":287},{"groupId":"EG001","numAffected":1,"numAtRisk":15},{"groupId":"EG002","numAffected":6,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":4,"numAtRisk":268},{"groupId":"EG003","numAffected":1,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Blood glucose increased","organSystem":"Investigations","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":287},{"groupId":"EG001","numAffected":1,"numAtRisk":15},{"groupId":"EG002","numAffected":6,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Blood magnesium decreased","organSystem":"Investigations","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":1,"numAtRisk":268},{"groupId":"EG003","numAffected":1,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Haemoglobin decreased","organSystem":"Investigations","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":287},{"groupId":"EG001","numAffected":1,"numAtRisk":15},{"groupId":"EG002","numAffected":1,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Lipase increased","organSystem":"Investigations","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":287},{"groupId":"EG001","numAffected":1,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Weight increased","organSystem":"Investigations","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":5,"numAtRisk":268},{"groupId":"EG003","numAffected":1,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Hypercholesterolaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":1,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Hypertriglyceridaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":1,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Hypocalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":1,"numAtRisk":15},{"groupId":"EG002","numAffected":6,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Hypomagnesaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":287},{"groupId":"EG001","numAffected":1,"numAtRisk":15},{"groupId":"EG002","numAffected":7,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":287},{"groupId":"EG001","numAffected":1,"numAtRisk":15},{"groupId":"EG002","numAffected":4,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Hypophosphataemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":287},{"groupId":"EG001","numAffected":1,"numAtRisk":15},{"groupId":"EG002","numAffected":3,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Muscle tightness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":1,"numAtRisk":15},{"groupId":"EG002","numAffected":1,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Muscular weakness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":287},{"groupId":"EG001","numAffected":1,"numAtRisk":15},{"groupId":"EG002","numAffected":6,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Musculoskeletal discomfort","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":287},{"groupId":"EG001","numAffected":1,"numAtRisk":15},{"groupId":"EG002","numAffected":2,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Musculoskeletal stiffness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":287},{"groupId":"EG001","numAffected":1,"numAtRisk":15},{"groupId":"EG002","numAffected":1,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Neck pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":287},{"groupId":"EG001","numAffected":1,"numAtRisk":15},{"groupId":"EG002","numAffected":4,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Pain in jaw","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":1,"numAtRisk":268},{"groupId":"EG003","numAffected":1,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Cognitive disorder","organSystem":"Nervous system disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":287},{"groupId":"EG001","numAffected":1,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Epilepsy","organSystem":"Nervous system disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":1,"numAtRisk":1}]},{"term":"Hypoaesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":287},{"groupId":"EG001","numAffected":1,"numAtRisk":15},{"groupId":"EG002","numAffected":4,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Memory impairment","organSystem":"Nervous system disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":287},{"groupId":"EG001","numAffected":1,"numAtRisk":15},{"groupId":"EG002","numAffected":1,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Motor dysfunction","organSystem":"Nervous system disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":1,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Transient ischaemic attack","organSystem":"Nervous system disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":287},{"groupId":"EG001","numAffected":1,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Confusional state","organSystem":"Psychiatric disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":287},{"groupId":"EG001","numAffected":1,"numAtRisk":15},{"groupId":"EG002","numAffected":5,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":10,"numAtRisk":268},{"groupId":"EG003","numAffected":1,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Breast pain","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":287},{"groupId":"EG001","numAffected":1,"numAtRisk":15},{"groupId":"EG002","numAffected":1,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Pneumonitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":2,"numAtRisk":268},{"groupId":"EG003","numAffected":1,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":4,"numAtRisk":268},{"groupId":"EG003","numAffected":1,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Rhinitis allergic","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":2,"numAtRisk":268},{"groupId":"EG003","numAffected":1,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Sputum discoloured","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":1,"numAtRisk":268},{"groupId":"EG003","numAffected":1,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Night sweats","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":287},{"groupId":"EG001","numAffected":1,"numAtRisk":15},{"groupId":"EG002","numAffected":5,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Toxic skin eruption","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":287},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":1,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":1,"numAtRisk":1}]},{"term":"Haematoma","organSystem":"Vascular disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":287},{"groupId":"EG001","numAffected":1,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Hot flush","organSystem":"Vascular disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":287},{"groupId":"EG001","numAffected":1,"numAtRisk":15},{"groupId":"EG002","numAffected":1,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":287},{"groupId":"EG001","numAffected":1,"numAtRisk":15},{"groupId":"EG002","numAffected":9,"numAtRisk":268},{"groupId":"EG003","numAffected":0,"numAtRisk":17},{"groupId":"EG004","numAffected":0,"numAtRisk":1}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication."},"pointOfContact":{"title":"Bristol-Myers Squibb Study Director","organization":"Bristol-Myers Squibb","email":"Clinical.Trials@bms.com","phone":"Please Email"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17","removedCountries":["South Africa","Turkey (Türkiye)"]},"interventionBrowseModule":{"meshes":[{"id":"D000077594","term":"Nivolumab"},{"id":"D000077143","term":"Docetaxel"}],"ancestors":[{"id":"D061067","term":"Antibodies, Monoclonal, Humanized"},{"id":"D000911","term":"Antibodies, Monoclonal"},{"id":"D000906","term":"Antibodies"},{"id":"D007136","term":"Immunoglobulins"},{"id":"D007162","term":"Immunoproteins"},{"id":"D001798","term":"Blood Proteins"},{"id":"D011506","term":"Proteins"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D012712","term":"Serum Globulins"},{"id":"D005916","term":"Globulins"},{"id":"D043823","term":"Taxoids"},{"id":"D043822","term":"Cyclodecanes"},{"id":"D003516","term":"Cycloparaffins"},{"id":"D006840","term":"Hydrocarbons, Alicyclic"},{"id":"D006844","term":"Hydrocarbons, Cyclic"},{"id":"D006838","term":"Hydrocarbons"},{"id":"D009930","term":"Organic Chemicals"},{"id":"D004224","term":"Diterpenes"},{"id":"D013729","term":"Terpenes"}]}},"hasResults":true}